{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:07:32Z","timestamp":1785240452493,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.03.018","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:07:34Z","timestamp":1776143254000},"page":"e829-e840.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan"],"prefix":"10.1016","volume":"26","author":[{"given":"Aaron S.","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-3115","authenticated-orcid":false,"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bulkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-8298","authenticated-orcid":false,"given":"Oliver","family":"Will","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Eliason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zander","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"DeCongelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.03.018_bib0001","unstructured":"Oracle, Oracle Life Sciences CancerMPact, in CancerMPact, Oracle. Patient Metrics Database."},{"issue":"10272","key":"10.1016\/j.clml.2026.03.018_bib0002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.clml.2026.03.018_bib0003","article-title":"Multiple myeloma unpacked","volume":"43","author":"Gay","year":"2025","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.clml.2026.03.018_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.clml.2026.03.018_bib0006","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.03.018_bib0007","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.03.018_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2010-S1-13","article-title":"The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology","volume":"15","author":"McKee","year":"2010","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.clml.2026.03.018_bib0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0b013e3181bdc2e0","article-title":"Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials","volume":"15","author":"Driscoll","year":"2009","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2026.03.018_bib0010","doi-asserted-by":"crossref","DOI":"10.3747\/co.20.1226","article-title":"Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer","volume":"20","author":"Cheema","year":"2013","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0011","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.03.018_bib0012","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0b013e3181b9c5ec","article-title":"Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development","volume":"15","author":"Lebwohl","year":"2009","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","article-title":"Should overall survival remain an endpoint for multiple myeloma trials?","volume":"14","author":"Holstein","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.018_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.018_bib0017","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1182\/blood-2024-201794","article-title":"How much has the overall survival of multiple myeloma patients improved after the incorporation of new drugs in the first line of treatment in real-world experience (RWE)?","volume":"144","author":"Ortega","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.018_bib0018","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clml.2017.12.009","article-title":"Single-center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation","volume":"18","author":"Chan","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.clml.2026.03.018_bib0019","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","article-title":"Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS Chart Review Study","volume":"24","author":"Gordan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2026.03.018_bib0021","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma","volume":"95","author":"Durie","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.018_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"10.1016\/j.clml.2026.03.018_bib0024","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.clml.2026.03.018_bib0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"5","key":"10.1016\/j.clml.2026.03.018_bib0026","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","article-title":"Best-worst scaling: what it can do for health care research and how to do it","volume":"26","author":"Flynn","year":"2007","journal-title":"J Health Econ"},{"issue":"12","key":"10.1016\/j.clml.2026.03.018_bib0028","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40273-016-0429-5","article-title":"Using best-worst scaling to investigate preferences in health care","volume":"34","author":"Cheung","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.03.018_bib0029","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2024-200333","volume":"144","author":"Cortes","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.03.018_bib0030","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/cancers13174320","article-title":"Choosing the right therapy for patients with relapsed\/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clml.2026.03.018_bib0031","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.clml.2026.03.018_bib0032","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.018_bib0033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-12-35","article-title":"Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma","volume":"12","author":"Proskorovsky","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1016\/j.clml.2026.03.018_bib0034","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jval.2020.04.1825","article-title":"EQ-5D-derived health state utility values in hematologic malignancies: a catalog of 796 utilities based on a systematic review","volume":"23","author":"Golicki","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pharp.2025.03.001","article-title":"A comparative analysis of EQ-5D-5L general population norms across 23 countries: gender and age disparities","volume":"1","author":"Wang","year":"2025","journal-title":"Pharmacoeconomics Policy"},{"key":"10.1016\/j.clml.2026.03.018_bib0036","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/PPA.S259612","article-title":"Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK","volume":"14","author":"Fifer","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.clml.2026.03.018_bib0037","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2026.03.018_bib0038","article-title":"Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment","volume":"10","author":"Thomas","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clml.2026.03.018_bib0039","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2147\/PPA.S474722","article-title":"Patient, care partner, and physician voices in treatment decision-making for multiple myeloma","volume":"18","author":"Dwyer Orr","year":"2024","journal-title":"Patient Prefer Adherence"},{"issue":"22","key":"10.1016\/j.clml.2026.03.018_bib0040","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2217\/fon-2023-0020","article-title":"Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA","volume":"19","author":"Ribbands","year":"2023","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.018_bib0041","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:55:53Z","timestamp":1785239753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S215226502600100X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}